Literature DB >> 26282217

MiR-661 contributed to cell proliferation of human ovarian cancer cells by repressing INPP5J expression.

Tongyu Zhu1, Jing Yuan2, Yuzhi Wang3, Cuiping Gong3, Yudou Xie3, Hong Li4.   

Abstract

Accumulating evidence has emerged important roles for microRNAs (miRNAs) participating in oncogenesis and growth of various cancers. We hypothesized that miR-661 played an important role in cell growth of ovarian cancer. Here, we found miR-661 was upregulated in human ovarian cancer cell lines and clinical tumor tissues. Our results revealed that miR-661 directly targeted INPP5J, thereby acting as tumor promoter in ovarian cancer cells by blocking cell proliferation. Importantly, we identified miR-661 as a positive regulator of INPP5J-induced AKT pathway. Taken together, our study sheds light onto the role of miR-661 as tumor promoter by targeting the INPP5J gene, and then promoting cell proliferation of ovarian cancer.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell proliferation; Human ovarian cancer; INPP5J; miR-661

Mesh:

Substances:

Year:  2015        PMID: 26282217     DOI: 10.1016/j.biopha.2015.07.023

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  18 in total

1.  miRNA-199a-5p suppresses proliferation and invasion by directly targeting NF-κB1 in human ovarian cancer cells.

Authors:  Xiaoxiao Liu; Baofeng Yao; Zhiming Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

2.  Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer.

Authors:  Xiaofang Han; Yan Zhang; Dong Wang; Xinyun Fu; Meiqing Li; Aiming Wang
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

3.  Hsa_circ_0103232 promotes melanoma cells proliferation and invasion via targeting miR-661/RAB3D.

Authors:  Xing Lin; Liang Zhong; Nian Wang; Xuan Chu; Beizhong Liu
Journal:  Cell Cycle       Date:  2022-05-13       Impact factor: 5.173

4.  circFAM120B functions as a tumor suppressor in esophageal squamous cell carcinoma via the miR-661/PPM1L axis and the PKR/p38 MAPK/EMT pathway.

Authors:  Huan Song; Dan Tian; Jian Sun; Xuhua Mao; Weimin Kong; Dian Xu; Ye Ji; Beibei Qiu; Mengyao Zhan; Jianming Wang
Journal:  Cell Death Dis       Date:  2022-04-18       Impact factor: 9.685

5.  MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non small cell lung cancer.

Authors:  Feiye Liu; Yanjun Cai; Xiaoxiang Rong; Jinzhang Chen; Dayong Zheng; Lu Chen; Junyi Zhang; Rongcheng Luo; Peng Zhao; Jian Ruan
Journal:  Mol Cancer       Date:  2017-07-17       Impact factor: 27.401

6.  New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer

Authors:  Ai Ling Liu; Hong Qing Liao; Zhi Liang Li; Jun Liu; Cui Lan Zhou; Zi Fen Guo; Hong Yan Xie; Cui Ying Peng
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

7.  MicroRNA-661 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation.

Authors:  Feifei Lv; Kehong Zheng; Jinlong Yu; Zonghai Huang
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

Review 8.  Research Progress of MicroRNA in Early Detection of Ovarian Cancer.

Authors:  Ze-Hua Wang; Cong-Jian Xu
Journal:  Chin Med J (Engl)       Date:  2015-12-20       Impact factor: 2.628

9.  MicroRNA-661 modulates redox and metabolic homeostasis in colon cancer.

Authors:  Marta Gómez de Cedrón; Rebeca Acín Pérez; Ruth Sánchez-Martínez; Susana Molina; Jesús Herranz; Jaime Feliu; Guillermo Reglero; Jose Antonio Enríquez; Ana Ramírez de Molina
Journal:  Mol Oncol       Date:  2017-11-06       Impact factor: 6.603

10.  Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses.

Authors:  Tran N Nguyen; Ha Q Nguyen; Duc-Hau Le
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.